PRF Technologies (PRFX) Other financing activities (2021 - 2025)

PRF Technologies (PRFX) posted quarterly Other financing activities of $8400.0 for Q4 2025, down 99.73% on a QoQ basis from $3.1 million in Q4 2023.

PRF Technologies (PRFX) Other financing activities (2021 - 2025) Analysis & Trends

PRF Technologies (PRFX) has reported Other financing activities for 3 consecutive years, with $8400.0 the latest figure, recorded in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $8400.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $219400.0 (changed N/A YoY) and the FY2025 annual result came in at $190000.0, down 94.0% from the prior year.
Other financing activities fell to $8400.0 in Q4 2025 per PRFX's latest filing, from $3.1 million in the prior quarter.
Over the last five years, Other financing activities for PRFX reached as high as $3.1 million in Q4 2023 and fell as low as -$2.3 million in Q2 2023.
A 3-year average of $358233.3 and a median of -$218800.0 in 2021 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	PRF Technologies	745,168.93	451,168.93	-

Download Data